市场调查报告书
商品编码
1298658
病毒载体制造市场:2023-2028年全球行业趋势、份额、规模、增长、机会和预测Viral Vector Manufacturing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 |
全球病毒载体制造市场规模在2022年达到9.61亿美元。展望未来,IMARC集团预计,到2028年,市场价值将达到39.75亿美元,在2023-2028年期间,增长率(CAGR)为24.9%。
病毒载体是分子生物学家用来将遗传物质送入细胞的一种工具。它被用来替换有缺陷的基因以治愈遗传性疾病,表达和呈现病原体抗原,通过模仿自然感染产生免疫反应。它被广泛地应用于溶瘤疗法,以瞄准和杀死肿瘤细胞。除此之外,由于它有助于治疗不同的疾病,如心脏缺陷、代谢性疾病和神经退行性疾病,它在生命科学研究、基因治疗和疫苗学方面有广泛的应用。目前,由于基因突变和体内染色体受损的结合,遗传性疾病的发病率不断上升,病毒载体制造也随之上升。
由于个人饮酒和久坐的生活方式的上升,癌症患者的增加代表了促进市场增长的关键因素之一。此外,全球范围内对病毒载体进行的临床研究数量也在增加。这一点,加上病毒载体在新型药物递送中的应用越来越多,正在对市场产生积极影响。除此之外,它们是病毒失能序列的有效载体,并被用来向人类造血干细胞(HSCs)传递抑制艾滋病毒的转基因。此外,一些国家的政府正在开展活动,以提高个人对病毒载体疫苗的认识。他们也在通过变革改善监管环境,如快速审批程序。此外,主要的市场参与者正在广泛地投资于世界各地的生产活动的产能扩张。这些参与者还沉迷于合併和收购(M&A),这预计会增加他们的整体销售和盈利能力。
The global viral vector manufacturing market size reached US$ 961 Million in 2022. Looking forward, IMARC Group expects the market to reach a value of US$ 3,975 Million by 2028, exhibiting a growth rate (CAGR) of 24.9% during 2023-2028.
A viral vector is a tool used by molecular biologists for delivering genetic materials into cells. It is used to replace defective genes for curing genetic disorders and express and present pathogenic antigens for generating an immune response by mimicking a natural infection. It is widely employed in oncolytic therapies to target and kill tumor cells. Besides this, as it assists in treating different diseases, such as heart defects, metabolic diseases, and neurodegenerative disorders, it finds extensive applications in life science research, gene therapy and vaccinology. At present, there is a rise in viral vector manufacturing on account of the rising prevalence of genetic disorders due to a combination of gene mutations and damaged chromosomes in the body.
The increasing cancer patients due to the rising alcohol consumption and sedentary lifestyles of individuals represents one of the key factors contributing to the growth of the market. In addition, there is a rise in the number of clinical studies undertaken on viral vectors across the globe. This, along with the growing utilization of viral vectors in novel drug delivery, is positively influencing the market. Besides this, they are efficient carriers of virus-disabling sequences and are used to deliver HIV-inhibiting transgenes to human hematopoietic stem cells (HSCs). Additionally, governments of several countries are launching campaigns to generate awareness about viral vector vaccines among individuals. They are also improving the regulatory environment via changes, such as fast-track approval processes. Furthermore, key market players are extensively investing in capacity expansion for manufacturing activities around the world. These players are also indulging in mergers and acquisitions (M&A), which is projected to increase their overall sales and profitability.
IMARC Group provides an analysis of the key trends in each sub-segment of the global viral vector manufacturing market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, disease, application and end user.
Adenoviral Vectors
Adeno-associated Viral Vectors
Lentiviral Vectors
Retroviral Vectors
Others
Cancer
Genetic Disorders
Infectious Diseases
Others
Gene Therapy
Vaccinology
Pharmaceutical and Biopharmaceutical Companies
Research Institutes
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Cognate BioServices Inc. (Charles River Laboratories International Inc.), F. Hoffmann-La Roche AG, FinVector Oy, FUJIFILM Holdings Corporation, Kaneka Eurogentec S.A. (Kaneka Corporation), Lonza Group AG, Merck KGaA, Oxford Biomedica plc, REGENXBIO Inc., Sanofi S.A., Thermo Fisher Scientific Inc. and uniQure N.V.
Key Questions Answered in This Report
1. What was the size of the global viral vector manufacturing market in 2022?
2. What is the expected growth rate of the global viral vector manufacturing market during 2023-2028?
3. What has been the impact of COVID-19 on the global viral vector manufacturing market?
4. What are the key factors driving the global viral vector manufacturing market?
5. What is the breakup of the global viral vector manufacturing market based on the type?
6. What is the breakup of the global viral vector manufacturing market based on the disease?
7. What is the breakup of the global viral vector manufacturing market based on the application?
8. What are the key regions in the global viral vector manufacturing market?
9. Who are the key players/companies in the global viral vector manufacturing market?